InvestorsHub Logo
Followers 35
Posts 2768
Boards Moderated 2
Alias Born 10/07/2010

Re: None

Wednesday, 09/30/2020 4:28:21 AM

Wednesday, September 30, 2020 4:28:21 AM

Post# of 26260
Some people are still doubting the relationship between Halberd Corp and ASU/The Biodesign Institute, even when there's hard evidence like the signed Research Agreement that's online and the updated "research timeline" of the principal investigator that's published on the ASU website. Every month for the coming 27 months they need to pay ASU $50,000 and they have to pay for their own expenses. They can't issue convertible loans and dilute the stock, but they don't need to because the project is fully funded.

The original plan was to develop, test and bring to market the extracorporeal treatment. In cooperation with ASU the development of a diagnostic tool was added and only days ago they announced the joint production of a preventative COVID-19 nasal spray. It's taking time but recent developments will take Halberd to the next level. My expectation is they will come up with new partners, probably a pharmaceutical company (existing producer of nasal sprays).

https://www.otcmarkets.com/filing/html?id=14147939&guid=tcj6UekP1eDse8h

https://halberdcorporation.com/wp-content/uploads/2020/09/ASU-K-Fully-Executed.pdf